U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C22H24ClFO7
Molecular Weight 454.873
Optical Activity UNSPECIFIED
Defined Stereocenters 5 / 5
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of HENAGLIFLOZIN

SMILES

CCOC1=CC=C(CC2=CC(=CC=C2Cl)[C@@]34OC[C@@](CO)(O3)[C@@H](O)[C@H](O)[C@H]4O)C=C1F

InChI

InChIKey=HYTPDMFFHVZBOR-VNXMGFANSA-N
InChI=1S/C22H24ClFO7/c1-2-29-17-6-3-12(8-16(17)24)7-13-9-14(4-5-15(13)23)22-20(28)18(26)19(27)21(10-25,31-22)11-30-22/h3-6,8-9,18-20,25-28H,2,7,10-11H2,1H3/t18-,19-,20+,21+,22+/m0/s1

HIDE SMILES / InChI
Molecular Formula C22H24ClFO7
Molecular Weight 454.873
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 5 / 5
E/Z Centers 0
Optical Activity UNSPECIFIED

Description

Henagliflozin (also known as SHR3824) was developed by Jiangsu HengRui Medicine as a sodium glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes mellitus. This drug successfully passed phase I clinical trials, however, information about further development is not available.

Originator

Approval Year

Unknown
139594
PubMed

PubMed

TitleDatePubMed
Evaluation of drug-drug interaction between henagliflozin, a novel sodium-glucose co-transporter 2 inhibitor, and metformin in healthy Chinese males.
2016 Aug

Sample Use Guides

In Vivo Use Guide
to evaluate the pharmacodynamics (PD), pharmacokinetics (PK), safety and tolerability following single and multiple oral doses of 5mg to 20 mg SHR3824 in Type 2 diabetes mellitus patients.
Route of Administration: Oral
Substance Class Chemical
Created
by admin
on Fri Dec 15 16:57:18 GMT 2023
Edited
by admin
on Fri Dec 15 16:57:18 GMT 2023
Record UNII
21P2M98388
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
HENAGLIFLOZIN
Common Name English
SHR-3824
Code English
Henagliflozin [WHO-DD]
Common Name English
SHR3824
Code English
.BETA.-D-GLUCOPYRANOSE, 1,6-ANHYDRO-1-C-(4-CHLORO-3-((4-ETHOXY-3-FLUOROPHENYL)METHYL)PHENYL)-5-C-(HYDROXYMETHYL)-
Systematic Name English
((1R,2S,3S,4R,5R)-5-(4-CHLORO-3-(4-ETHOXY-3-FLUOROBENZYL)PHENYL)-1-(HYDROXYMETHYL)-6,8-DIOXABICYCLO(3.2.1)OCTANE-2,3,4-TRIOL
Systematic Name English
Code System Code Type Description
FDA UNII
21P2M98388
Created by admin on Fri Dec 15 16:57:18 GMT 2023 , Edited by admin on Fri Dec 15 16:57:18 GMT 2023
PRIMARY
PUBCHEM
56832738
Created by admin on Fri Dec 15 16:57:18 GMT 2023 , Edited by admin on Fri Dec 15 16:57:18 GMT 2023
PRIMARY
DRUG BANK
DB11939
Created by admin on Fri Dec 15 16:57:18 GMT 2023 , Edited by admin on Fri Dec 15 16:57:18 GMT 2023
PRIMARY
CAS
1623804-44-3
Created by admin on Fri Dec 15 16:57:18 GMT 2023 , Edited by admin on Fri Dec 15 16:57:18 GMT 2023
PRIMARY
Related Record Type Details
SODIUM/GLUCOSE COTRANSPORTER 2
TARGET -> INHIBITOR
Structure of HENAGLIFLOZIN PROLINE
SALT/SOLVATE -> PARENT
Related Record Type Details
Structure of HENAGLIFLOZIN
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966